Backed by patent expiration and desire to reduce healthcare cost, the US generic market is likely to grow at a CAGR of 10% during 2010-2013, says RNCOS.
(prHWY.com) March 5, 2012 - NOIDA, India -- As per our new research report, "Booming US Generic Drug Market", the US generics market has witnessed stupendous growth in recent times driven mainly by patent expiration of key blockbuster drugs. As both consumers and the governments are trying to reduce healthcare costs, the country is experiencing a renowned focus on generics by both the entities. In 2009, the US generic drugs sector was valued at US$ 74 Billion, and is likely to grow further at a CAGR of around 10% during 2010-2013. In value terms, generic drugs will contribute a share of around 28% in the US pharmaceutical market by 2013.
The report has identified that the US generics antidepressant market holds a significant growth potential in the years to come. Despite a stable growth rate pattern, the market will seek a boost in future backed by significant investment and product launches. With the patent expiration of Wyeth's antidepressant drug Effexor XR, the market is slowly becoming competitive and new generics will further strengthen the participation of the private sector. A long acting version of Prozac patent is expected to expire in 2017, which will again boost growth in the sector.
The report, "Booming US Generic Drug Market", evaluates the key drivers spurring the industry's growth and major challenges confronted by the industry. It covers all the important aspects of the US generics market and provides a prudent analysis on the emerging trends, such as injectable generics, anti-counterfeit coalition, and bio-generics among others. Moreover, it also covers a detailed analysis on key therapeutic segments in generics, such as lipid regulator, human insulin, antipsychotics, anti-depressants, etc.
The report is an outcome of an extensive research and prudent analysis on the US generic drugs market that provides reliable statistics and in-depth insight. It effectively evaluates the current and future performance of the market and makes use of proper techniques for forecasting. Moreover, information on key players, their recent activities and SWOT analysis have been included in the report. Overall, the clients will obtain an optimum insight into the US generics market through this analysis covered in this report.
For FREE SAMPLE of this report visit:
http://www.rncos.com/Report/IM589.htm
Some of our Related Reports are:
- Generic Drug Market in Canada (
http://www.rncos.com/Report/IM598.htm)
- Cancer Generics Market Analysis (
http://www.rncos.com/Report/IM353.htm)
- Booming Generics Drug Market in India (
http://www.rncos.com/Report/IM256.htm)
- UK Generics Market Analysis (
http://www.rncos.com/Report/IM313.htm)
- Japanese Generic Market Forecast to 2013(http://www.rncos.com/Report/IM170.htm)
Check Related REPORTS on:
http://www.rncos.com/Healthcare.htm
About RNCOS
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.
###